NKG2A, a New Kid on the Immune Checkpoint Block

• John B. Haanen ^[2] ; Vincenzo Cerundolo ^[1]
  1. [1] University of Oxford

     University of Oxford

     Oxford District, Reino Unido

     
  2. [2] The Netherlands Cancer Institute
• Localización: Cell, ISSN 0092-8674, Vol. 175, Nº. 7, 2018, págs. 1720-1722
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8+ T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.